Anti-Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support

JACC: Heart Failure

Volumn 3, Issue 4, 2015, Pages 314-322

  Adatya, Sirtaz ^a   Uriel, Nir ^b   Yarmohammadi, Hirad ^a   Holley, Christopher T ^a   Feng, Amy ^a   Roy, Samit S ^a   Reding, Mark T ^a   John, Ranjit ^a   Eckman, Peter ^a   Zantek, Nicole D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Activated partial thromboplastin time; Anti factor Xa; Anti FXa; APTT; CF LVAD; Continuous flow left ventricular assist device; INR; Intravenous unfractionated heparin; IV UFH; LDH; Monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; ASSISTED CIRCULATION; BLEEDING; CLINICAL ARTICLE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; DEVICE FAILURE; DEVICE THROMBOSIS; DRUG MONITORING; DRUG SAFETY; FEMALE; HEART FAILURE; HEMOLYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOEMBOLISM; THROMBOSIS; ADVERSE EFFECTS; DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART ASSIST DEVICE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSTHESIS FAILURE; TREATMENT OUTCOME;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART-ASSIST DEVICES; HEMOLYSIS; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84926419772     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.11.009     Document Type: Article

References (24)

1. Starling R.C., Moazami N., Silvestry S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. NEngl J Med 2014, 370:33-40.
2. Kirklin J.K., Naftel D.C., Kormos R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. JHeart Lung Transplant 2014, 33:12-22.
3. Mehra M.R., Stewart G.C., Uber P.A. The vexing problem of thrombosis in long-term mechanical circulatory support. JHeart Lung Transplant 2014, 33:1-11.
4. Guervil D.J., Rosenberg A.F., Winterstein A.G., Harris N.S., Johns T.E., Zumberg M.S. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011, 45:861-868.
5. Takemoto C.M., Streiff M.B., Shermock K.M., et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 2013, 139:450-456.
6. Price E.A., Jin J., Nguyen H.M., Krishnan G., Bowen R., Zehnder J.L. Discordant aPTT and anti-Xavalues and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother 2013, 47:151-158.
7. Kearon C., Johnston M., Moffat K., McGinnis J., Ginsberg J.S. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998, 158:1140-1143.
8. Baker B.A., Adelman M.D., Smith P.A., Osborn J.C. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997, 157:2475-2479.
9. Slaughter M.S., Naka Y., John R., et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. JHeart Lung Transplant 2010, 29:616-624.
10. Brill-Edwards P., Ginsberg J.S., Johnston M., Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993, 119:104-109.
11. Olson J.D., Arkin C.F., Brandt J.T., et al. College ofAmerican Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998, 122:782-798.
12. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:141S-159S.
13. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001, 119:64S-94S.
14. Hochman J.S., Wali A.U., Gavrila D., et al. Anew regimen for heparin use in acute coronary syndromes. Am Heart J 1999, 138:313-318.
15. Rosborough T.K., Shepherd M.F. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 2004, 24:713-719.
16. Rosenberg A.F., Zumberg M., Taylor L., LeClaire A., Harris N. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. JPharm Pract 2010, 23:210-216.
17. Levine M.N., Hirsh J., Gent M., et al. Arandomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994, 154:49-56.
18. Hull R.D., Raskob G.E., Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. NEngl J Med 1990, 322:1260-1264.
19. Vandiver J.W., Vondracek T.G. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012, 32:546-558.
20. Renne T., Schmaier A.H., Nickel K.F., Blomback M., Maas C. Invivo roles of factor XII. Blood 2012, 120:4296-4303.
21. Kuijpers M.J., van der Meijden P.E., Feijge M.A., et al. Factor XII regulates the pathological processof thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014, 34:1674-1680.
22. Gehrie E., Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol 2012, 87:194-196.
23. Kitchens C.S. To bleed or not to bleed? Is that the question for the PTT?. JThromb Haemost 2005, 3:2607-2611.
24. Eikelboom J.W., Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006, 96:547-552.